everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...7172737475767778798081...132133»
  • ||||||||||  Afinitor (everolimus) / Novartis, doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
    [VIRTUAL] EFFICACY, EFFECTIVENESS, AND SAFETY OF FRONTLINE TREATMENTS FOR PERIPHERAL T-CELL LYMPHOMA () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_463;    
    There is limited efficacy/effectiveness data by PTCL subtypes, and limited safety and HRQoL data. Future studies should explore the effectiveness, safety, and HRQoL impact of frontline treatments especially in the rare PTCL subtypes.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine. (Pubmed Central) -  Mar 7, 2020   
    Both, the mTOR inhibitor everolimus as well as antiangiogenetic effects by the VEGFR inhibitor axitinib showed potential to prevent and retard formation of symptomatic spinal metastases. However, the therapeutic efficacy was only mild in this experimental model.
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] Metabolomic adaptations and correlates of survival to immune checkpoint blockade (Hall G-H - Upper Lvl - SDCC) -  Mar 6, 2020 - Abstract #AACR2020AACR_1187;    
    By using independent cohorts, we showed that Kyn/Trp temporal alterations robustly correlated with overall survival of patients receiving nivolumab. Our findings illustrate that checkpoint blockade in combination with IDO/TDO inhibitors might only benefit a selected group of patients with checkpoint-inhibition-triggered kynurenine pathway activation.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    Enrollment open, Trial initiation date:  Implantable Microdevice In Primary Brain Tumors (clinicaltrials.gov) -  Mar 5, 2020   
    P1,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jul 2021 | Trial primary completion date: Mar 2020 --> Dec 2019 Not yet recruiting --> Recruiting | Initiation date: Nov 2019 --> Mar 2020
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal, HEOR:  Treatment sequences for advanced renal cell carcinoma: A health economic assessment. (Pubmed Central) -  Mar 4, 2020   
    Treatment sequences using nivolumab in the second-line setting are less costly compared with sequential use of targeted agents. In addition to efficacy and safety data, cost considerations may be taken into account when considering treatment algorithms for patients with advanced RCC.
  • ||||||||||  Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
    Trial initiation date, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases:  MEGALiT: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (clinicaltrials.gov) -  Mar 4, 2020   
    P2,  N=154, Not yet recruiting, 
    In addition to efficacy and safety data, cost considerations may be taken into account when considering treatment algorithms for patients with advanced RCC. Initiation date: Jan 2020 --> Apr 2020
  • ||||||||||  fluorouracil / Generic mfg., Afinitor (everolimus) / Novartis
    Journal:  Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system (Pubmed Central) -  Mar 2, 2020   
    For symptom control in patients with carcinoid syndrome biotherapy with somatostatin analogs, PRRT, loco-regional and local-ablative interventional procedures of liver metastases as well as the peripheral serotonin synthesis inhibitor telotristat Ethyl 1 2 3 4 are highly effective. Novel aspects and developments in the diagnosis and treatment of neuroendocrine tumors will be discussed in this review.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  RAD001 for Patients With Radioiodine Refractory Thyroid Cancer (clinicaltrials.gov) -  Mar 2, 2020   
    P2,  N=50, Completed, 
    The dual-targeting strategy developed in this study in conjunction with a potentially promising delivery vector for a synergistic combination therapy can overcome receptor heterogeneity, yielding significant improvements in the cytotoxicity and cellular uptake in BC cells. Active, not recruiting --> Completed | N=33 --> 50 | Trial completion date: Dec 2021 --> Feb 2020 | Trial primary completion date: Dec 2020 --> Feb 2020
  • ||||||||||  Afinitor (everolimus) / Novartis
    Review, Journal:  Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. (Pubmed Central) -  Feb 27, 2020   
    The use of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors palbociclib, ribociclib and abemaciclib of the mammalian target of rapamycin (mTOR) inhibitor everolimus and of the phosphoinositide 3 kinase (PI3K) inhibitor taselisib together with endocrine therapy (ET) has become a standard in advanced breast cancer, showing clinical effectiveness and significantly prolonging median progression-free survival compared to ET only...In this context, the use of genomic-transcriptomic tools (such as ONCOTYPE, PAM50) and the identification of novel biomarkers (ESR1, PI3Kca, PDGF-R) on tissue or with liquid biopsy could help to select patient prone to respond to endocrine-combined therapy and able to achieve pCR. With our review, we aimed at evaluating the current state of the art in the treatment of locally advanced breast cancer with NEO-HT.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Monotherapy:  Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma (clinicaltrials.gov) -  Feb 27, 2020   
    P2,  N=4, Active, not recruiting, 
    Research Funding: Hutchison MediPharma International Inc Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Feb 2020 --> Feb 2021
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. (Pubmed Central) -  Feb 26, 2020   
    P1/2
    Effects from mTOR overactivity on white matter microstructural integrity in TSC were modified through pharmacologic inhibition of mTOR. These changes sustained over time, were greater with longer treatment and in younger patients during a time of rapid white matter maturation.
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Review, Journal, Combination therapy, Checkpoint inhibition:  New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. (Pubmed Central) -  Feb 26, 2020   
    In metastatic renal cell carcinoma (mRCC) the PD-1 immune-checkpoint inhibitor (ICI) Nivolumab became a standard second line treatment option in 2015 based on a significant improvement of overall survival compared to Everolimus...Nivolumab plus Ipilimumab is characterized by a survival advantage, a high rate of complete response and durable remissions in intermediate and poor prognosis patients...Pembrolizumab or Avelumab plus Axitinib were characterized by an improved progression-free-survival and a high response rate with a low rate of intrinsic resistance...The quality of life data published so far do not suggest any improvement regarding patient-reported outcomes compared to the previous standard Sunitinib. The PD-1/PD-L1 ICIs thus form the backbone of the first-line therapy of mRCC.
  • ||||||||||  Afinitor (everolimus) / Novartis, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal, HEOR:  Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma. (Pubmed Central) -  Feb 25, 2020   
    No abstract available Combining pharmacologic costs of drugs with the measure of efficacy represented by OS, cabozantinib is a cost-effective second-line treatments for patients with mRCC.
  • ||||||||||  Avastin (bevacizumab) / Roche, everolimus / Generic mfg.
    P2 data, Journal:  Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. (Pubmed Central) -  Feb 25, 2020   
    It has been reported in several tumour types but has never been described as a consequence of NET. Combining everolimus and bevacizumab does not distinctly improve response compared to bevacizumab alone, but further study of selected patients with alterations in the PI3K/mTOR pathway may document benefit.
  • ||||||||||  vistusertib (AZD2014) / AstraZeneca
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  MANTA: A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer (clinicaltrials.gov) -  Feb 25, 2020   
    P2,  N=333, Active, not recruiting, 
    Combining everolimus and bevacizumab does not distinctly improve response compared to bevacizumab alone, but further study of selected patients with alterations in the PI3K/mTOR pathway may document benefit. Trial completion date: Jun 2019 --> Jul 2020 | Trial primary completion date: Jun 2019 --> Jul 2020
  • ||||||||||  tacrolimus / Generic mfg., Afinitor (everolimus) / Novartis
    Dubai took my breath away (TBA) -  Feb 24, 2020 - Abstract #BWG2020BWG_190;    
    Six years ago, he underwent an orthotopic liver transplantation because of alcoholic liver cirrhosis with a small HCC (2 cm), taking immunosuppressive medication (everolimus and mycophenolic acid)...For that matter, everolimus was replaced by tacrolimus...[1,2] Therefore, clinical suspicion needs to be high in every patient treated with a mTOR inhibitor (sirolimus as well as everolimus) presenting with new onset of pulmonary symptoms. Representative lung CT images can be shown during case presentation.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin (clinicaltrials.gov) -  Feb 23, 2020   
    P2,  N=30, Recruiting, 
    Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021 Trial completion date: May 2017 --> Dec 2021 | Trial primary completion date: Jan 2017 --> Dec 2021